217.42
+1.97%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jagsonpal Pharmaceuticals
Its shares trade on NSE under the ticker JAGSNPHARM.NS. It has been listed since 13 September 1996. In the fiscal year to 31 March 2026, it reported revenue of ₹2.87bn and net income of ₹430.8m. At that date it held total assets of ₹3.17bn and shareholders' equity of ₹2.76bn.
Jagsonpal Pharmaceuticals Ltd. is a pharmaceutical company, which engages in the development and manufacture of intermediate drugs and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Company’s therapy areas include gynecology, orthopedics, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Sept 1996
- Employees
- 940
- Website
- jagsonpal.com ↗
Leadership
Pay as last reported
- Mr. Rajpal KochharChairman Emeritus, since 2022₹10.1m
- Mr. Harsha RaghavanNon-Executive Chairman of the Board
- Mr. Nirav VoraChief Financial Officer
- Mr. Amrut MedhekarChief Operating Officer
- Mr. Pratham RawalCompliance Officer, Company Secretary₹66,164
- Mr. Manish GuptaManaging Director, Director, since 2022₹24.4m
- Mr. Prithipal KochharNon-Executive Director
- Ms. Radhika DudhatNon-Executive Independent Director₹1.4m
- Ms. Pallavi GuptaNon-Executive Independent Director₹1.5m
- Mr. Debasis NandyNon-Executive Independent Director₹1.6m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jagsonpal Pharmaceuticals Ltd employs 940 full-time employees in New Delhi, India.
- The company manufactures a diverse range of pharmaceutical formulations including Divatrone and Maintane injections.
- Jagsonpal offers specialized products like LycoRed softgels and Cystelia M for gynecology and orthopedics.
Weaknesses
- The company's product portfolio includes only a few OTC items such as Ringcuter Cream and Skin Lumia Soap.
- Jagsonpal Pharmaceuticals has limited presence in international markets beyond India.
- Jagsonpal's business is primarily focused on manufacturing and trading without significant R&D investment.
Opportunities
- Expanding the Naari product line to include Endoreg and Yuliprist for women's health could increase market share.
- Growing demand for gynecology and orthopedics therapies presents opportunities for Jagsonpal Pharmaceuticals.
- The company can leverage its existing API manufacturing capabilities to enter new markets.
Threats
- Competition from established pharmaceutical companies in the Indian market poses a threat to Jagsonpal's growth.
- Regulatory changes in the Indian pharmaceutical sector could impact Jagsonpal's operations.
- Increasing costs of raw materials may affect Jagsonpal's profit margins.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.